Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pricing Debate

Set Alert for Pricing Debate
Scrip Pricing Debate

Patent Settlements and Medicare Negotiation: What Leverage Does Pharma Have To ‘Game’ Price Reform?

Brand drug companies might be able to use patent settlements with generic and biosimilar makers to get out of the drug price negotiations that will be created under the US legislation nearing enactment, but sponsors could run into regulatory and antitrust obstacles.

Legislation Pricing Debate

Quick Listen: Scrip's Five Must-Know Things

In this week's podcast version of Five Must-Know Things: planned US drug pricing legislation in focus; solid quarter but no Seagen announcement for Merck & Co; AbbVie’s Gonzalez sounds alarm over US pricing legislation; Alnylam ready to expand in amyloidosis; and Boehringer Ingelheim on global Jardiance strategy.

Pricing Debate Sales & Earnings

As Lilly’s Realized Sales Prices Drop, Ricks Reiterates Criticism Of US Drug Price Plan

With Lilly’s sales narrative hampered by global price pressures, Lilly CEO David Ricks again criticized drug price negotiation proposals before Congress. Mounjaro launch offers a bright spot, exceeding projections.

Sales & Earnings Business Strategies

Don’t Look Up? Investors Call For Tweaks To Small Molecule Provisions In US Pricing Bill

Investors and pharma stakeholders scramble to extend the time period before small molecule drugs are subject to government mandated discounts as Senate drug pricing legislation moves toward a floor vote.

Pricing Debate Legislation

Pharma Braces For Potential Landmark Moment For US Drug Price Controls

US drug pricing legislation that has picked up momentum could stymie R&D investment and curb the revenue tail for some big drugs, industry says, but CEOs also expect they can navigate the challenge. 

Legislation Pricing Debate

AbbVie’s Gonzalez Sounds Alarm On US Drug Price Negotiation Proposal

AbbVie posts solid quarter on strength of Skyrizi growth and continued US growth for Humira ahead of patent expiry. Imbruvica revenue continues to decline, however.

Sales & Earnings Pricing Debate

Novo Nordisk's Obesity Drugs Exceed ICER’s Cost Effectiveness Thresholds

Wegovy and Saxenda surpass cost effectiveness thresholds at current prices, while two widely unused drugs, Qysmia and Contrave, are cost-effective at accepted benchmarks, according to a draft report from the Institute for Clinical and Economic Review.

Cost Effectiveness Metabolic Disorders

HHS Price Negotiations Could Be Delayed When Biologics Have Biosimilars Pending Under Bill

Latest iteration of drug pricing legislation from Senate Democrats would also firm up the number of drugs HHS must choose for price negotiation each year and no longer treats insulin as a separate class for purposes of negotiation.

Pricing Debate Medicare

FTC To Investigate PBM Practices, Including Focus On Consumer Costs, Access

Federal Trade Commission study of the six largest pharmacy benefit managers in the US wins the unanimous support of commissioners after its scope was broadened from an earlier version.

Pricing Debate Policy

The Story of Aduhelm, From Early Studies To Commercial Demise

Our graphical timeline walks you through the most significant events in the history of the Alzheimer’s drug, including the tumultuous last year.

Review Pathway Drug Approval Standards

Beyond COVID-19 Spending Growth, Biosimilars Slowed Growth In Other Categories

The COVID-19 windfall meant a 12% rise in spending on medicines in the US in 2021 versus 2020, but just 5% excluding COVID, which is expected to fall to 1%-4% compound annual growth through 2026.

Biosimilars Coronavirus COVID-19

Civica Takes On The Challenge Of Insulin Affordability

The non-profit organization plans to make biosimilar versions of Lantus, Humalog and Novolog and sell them for no more than $30/vial.

Biosimilars Pricing Strategies
See All
UsernamePublicRestriction

Register